Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMISH0Z)

Drug Name

Mogamulizumab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Mycosis fungoides	2B01	Approved	[1]
Sezary syndrome	2B02	Approved	[1]
Cutaneous T-cell lymphoma	2B01	Phase 3	[2]
T-cell leukaemia	2A90	Phase 2	[2]
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[2]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
C-C chemokine receptor type 4 (CCR4)	TT7HQD0	CCR4_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
C-C chemokine receptor type 4 (CCR4)	DTT	CCR4	5.07	5.952	5.771	5.138

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Mycosis fungoides

ICD Disease Classification

2B01

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
C-C chemokine receptor type 4 (CCR4)	DTT	CCR4	2.33E-02	3.98E-03	0.03

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma. Curr Opin Mol Ther. 2010 Dec;12(6):770-9.